Sarcopenia and the protein question: 74 randomised trials, and what they could not settle

A meta-analysis of 74 randomised controlled trials finds that raising daily protein intake adds a small amount of lean mass and lower-body strength in adults in resistance training, with a barely significant effect on bench press, an unclear effect on grip strength, and a minimal effect on physical function tests.

goodWell supported, with the usual caveats about effect size.Revised 04 Nov 2026

A plain glass of water and a small white bowl of nuts on a pale kitchen table beside a closed notebook

The largest synthesis on protein intake and muscle in healthy adults, and the point where its effect stops.

Sarcopenia is defined as the loss of muscle mass and function — the “and” is in the definition, and most of the research around it quietly drops it. A 2022 meta-analysis of 74 randomised controlled trials is the most thorough available look at the intervention that everybody actually recommends, and its result has a shape that is worth describing precisely: it works, a bit, for mass and strength, and almost not at all for function.

What the meta-analysis pooled

The question was whether raising daily protein intake leads to more lean body mass, more strength and better physical performance. The protocol was registered (PROSPERO CRD42020159001), and the search covered Medline, Embase, CINAHL and Web of Science. Only randomised controlled trials in healthy, non-obese adults who increased their daily protein intake were eligible. Subgroups split by participation in resistance exercise, by age (under 65 or 65 and over) and by level of protein ingestion. The synthesis used three-level random-effects models.

Seventy-four randomised trials. Most of them tested additional protein during resistance exercise training, which matters for reading everything that follows.

The results, in the order they were reported

Lean body mass: increasing daily protein may enhance gains in studies enrolling subjects in resistance exercise, standardised mean difference 0.22, 95% confidence interval 0.14 to 0.30, p below 0.01, across 62 studies, at a moderate level of evidence.
The mass effect was significant in subjects 65 and over ingesting 1.2 to 1.59 grams of protein per kilogram of body weight per day, and in younger subjects below 65 ingesting at least 1.6 grams per kilogram per day when doing resistance exercise.
Lower-body strength: slightly higher gains at higher intakes during resistance training, standardised mean difference 0.40, confidence interval 0.09 to 0.35, p below 0.01, 19 studies, at a low level of evidence.
Bench press strength: slightly increased in under-65s during resistance training, standardised mean difference 0.18, confidence interval 0.03 to 0.33, p = 0.01, 32 studies, low level of evidence.
Handgrip strength: unclear.
Physical function test performance: only marginal.

The authors’ own conclusion: increasing daily protein ingestion results in small additional gains in lean body mass and lower-body muscle strength gains, a slight effect on bench press strength, and a minimal effect on performance in physical function tests.

Why the distinction is the whole point

An effect size of 0.22 on lean mass sounds unimpressive until you know what it is sitting next to: a graded resistance programme. This is an add-on to training, not a substitute for it, and the trial base is overwhelmingly people who were already doing resistance exercise.

The functional result is the one a reader over fifty cares about, and it is where the analysis goes quiet. Handgrip strength: unclear. Physical function tests: marginal. Those are the endpoints that map onto stairs, walking and getting up from a chair — and they are the endpoints that define sarcopenia in the first place.

The 2023 sarcopenia review in Metabolism puts the same gap in a single sentence about the entire drug category: although some drugs have improved muscle mass and/or strength, this was not translated into clinically relevant improvements on physical performance. It also notes that strength exercise training and nutritional support remain the frontline treatment, with no drug approved for the indication.

For the pharmacological side of the same problem — the drugs that target muscle loss directly — peptheon.eu has written up where the myostatin and follistatin work currently stands: myostatin inhibitors and follistatin.

What this evidence does not show

Nothing about people with sarcopenia. The eligibility criteria were healthy, non-obese adults. The paper is not about the diagnosis.
Nothing about function. Handgrip strength is reported as unclear and physical function test performance as minimal. That is the honest gap.
The strength estimates rest on low-level evidence. The paper grades the lower-body and bench press findings as low certainty, and the lean mass finding as moderate. Only the mass result carries a moderate grade.
The confidence interval for lower-body strength, 0.09 to 0.35, sits oddly against the point estimate of 0.40 as printed in the abstract. The paper reports it that way; it is not a figure this article has adjusted or corrected.
Most trials studied protein taken alongside resistance training, so the results do not transfer to people who are not training.
No safety, adherence or long-term outcome data are pooled here.

The line

Seventy-four trials, and the honest reading is two sentences: more protein, on top of training, adds a small amount of lean mass and lower-body strength in adults who are healthy — and the effect on performance, the outcome that defines the disease this conversation started from, is marginal. The gap between those two sentences is where the field’s optimism usually gets added.